


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**ESTABLISH STRATEGIC JOINT VENTURE WITH TEMPO SCAN TO EXPAND
ACCESS TO INNOVATIVE MEDICINE IN INDONESIA**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group has entered into a joint venture agreement with PT Tempo Scan Pacific Tbk (“**Tempo Scan**”) to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (“**TCBI**”).

This joint venture (“**JV**”) combines the Group’s strong research, development, product pipeline capabilities and its broader internationalization strategy with Tempo Scan’s extensive manufacturing, regulatory, sales & marketing, and nationwide pharmaceutical distribution capabilities. Tempo Scan’s long-established reputation, integrated healthcare products manufacturing capabilities and nationwide logistic infrastructure positioned Tempo Scan as an ideal strategic partner for the Group’s long-term development in Indonesia. The Group contributes a differentiated product portfolio across first-to-market branded and innovative therapies, covering oncology, specialty care, cardio-metabolic and other therapeutic areas, thereby creating a platform to advance access to high-quality and innovative medicines for Indonesian patients. Together, the partnership establishes a long-term platform to accelerate the introduction of innovative medicines, strengthen the specialty pharmaceutical capabilities, and improve patient access across Indonesia.

The newly established joint venture, in which the Group holds a 51% majority stake while Tempo Scan owns 49% remaining stake, combines Tempo Scan’s deep local market expertise with the Group’s R&D and extensive products pipeline. The JV will focus on the regulatory expertise, medical affairs, clinical trials, market entry, and commercialization of a broad range of pharmaceutical products, and where appropriate, evaluate opportunities for future local manufacturing in Indonesia. Several products have already received regulatory approval or are currently under regulatory review, providing a solid

foundation for the joint venture's future growth. The JV is preparing to commence operations, with an initial portfolio of specialty pharmaceutical products that will be introduced progressively following regulatory approvals and the completion of operational readiness activities.

Indonesia: A Strategic Pharmaceutical Market

Indonesia is Southeast Asia's largest pharmaceutical market, with estimated long-term annual growth of approximately 8–10%. Supported by a population of more than 278 million, expanding universal healthcare coverage (JKN), and increasing life expectancy as well as growing demand for innovative therapies, henceforth Indonesia represents one Southeast Asia's largest and fastest-growing pharmaceutical markets offering significant long-term growth opportunities for innovative pharmaceutical companies.

For the Group, Indonesia is an important strategic market within its broader international development strategy. Through collaboration with a trusted local partner, the Company aims to accelerate the introduction of innovative medicines while contributing to the continued development of Indonesia's healthcare ecosystem.

Tempo Scan: A Trusted Indonesian Healthcare Partner

Established in 1953 and listed on the Indonesia Stock Exchange in 1994, Tempo Scan has built more than seven decades of experience in the manufacturing, marketing, distribution and commercialization of pharmaceutical products, consumer healthcare products, dairy nutrition including infant formula and personal care & hygiene products. Together with its subsidiaries, Tempo Scan operates 16 manufacturing facilities and one of the largest sales & marketing and distribution networks, with 238 distribution and logistics locations, comprising 4 distribution centers, 46 branches and warehouses, 13 sales offices, 173 sales points, and 2 e-commerce fulfillment services. This nationwide infrastructure enables Tempo Scan to deliver more than 1.8 million offline shipments and over 3.5 million online shipments annually across Indonesia.

Tempo Scan has successfully developed numerous market-leading brands across pharmaceuticals, consumer healthcare, personal care, personal hygiene and nutritional categories including infant formula. Tempo Scan's core brand equities are household names with leading market shares within their respective product categories. Tempo Scan's integrated capabilities in manufacturing, regulatory affairs, commercialization and nationwide distribution make it a strategic partner for bringing innovative pharmaceutical products to patients across Indonesia.

Advancing Long-Term Healthcare Collaboration

The joint venture reflects the shared commitment of both companies to improving patient access to innovative therapies while supporting the long-term development of Indonesia's pharmaceutical industry.

The companies are advancing a portfolio of specialty and innovative pharmaceutical products through various stages of registration and commercialization. Product launches will be implemented progressively in accordance with regulatory approval, with several products already approved or currently under regulatory review.

Beyond commercial collaboration, both parties will continue to explore broader opportunities in scientific exchange, local clinical development, manufacturing technology transfer and potential local manufacturing, supporting Indonesia's ambition to strengthen its pharmaceutical industry and healthcare ecosystem.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 27 July 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.